http://jnci.oxfordjournals.org/content/106/9/dju203.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/106/9/dju203" />
      <meta content="/jnci/106/9/dju203.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/dju203" name="DC.Identifier" />
      <meta content="2014-09-01" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Aiko Nagayama" name="DC.Contributor" />
      <meta content="Tetsu Hayashida" name="DC.Contributor" />
      <meta content="Hiromitsu Jinno" name="DC.Contributor" />
      <meta content="Maiko Takahashi" name="DC.Contributor" />
      <meta content="Tomoko Seki" name="DC.Contributor" />
      <meta content="Akiko Matsumoto" name="DC.Contributor" />
      <meta content="Takeshi Murata" name="DC.Contributor" />
      <meta content="Hutan Ashrafian" name="DC.Contributor" />
      <meta content="Thanos Athanasiou" name="DC.Contributor" />
      <meta content="Koji Okabayashi" name="DC.Contributor" />
      <meta content="Yuko Kitagawa" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Aiko Nagayama" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Tetsu Hayashida" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Hiromitsu Jinno" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Maiko Takahashi" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Tomoko Seki" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Akiko Matsumoto" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Takeshi Murata" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Hutan Ashrafian" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Thanos Athanasiou" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Koji Okabayashi" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta name="citation_author" content="Yuko Kitagawa" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); Department of Surgery and Cancer, Imperial College London, London, UK (HA, TA)." />
      <meta content="Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis"
            name="citation_title" />
      <meta content="09/01/2014" name="citation_date" />
      <meta content="106" name="citation_volume" />
      <meta content="9" name="citation_issue" />
      <meta content="dju203" name="citation_firstpage" />
      <meta content="106/9/dju203" name="citation_id" />
      <meta content="106/9/dju203" name="citation_id_from_sass_path" />
      <meta content="jnci;106/9/dju203" name="citation_mjid" />
      <meta content="10.1093/jnci/dju203" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/106/9/dju203.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/106/9/dju203.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/106/9/dju203.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/106/9.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/106/9/dju203"
            name="citation_public_url" />
      <meta content="25224562" name="citation_pmid" />
      <meta name="citation_section" content="Review" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/106/9/dju246.short" rel="prev" />
      <link href="/content/106/9/dju259.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d28094272e1">var callbackToken='537A73B9B0E9899';</script><script type="text/javascript" id="session-d28094272e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:15:07.774-07:00';
            var gSessionId = 'df9kUmJpoCGf4AwEzAI@YQ';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/dju203");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20140901");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F106%2F9%2Fdju203.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/106/9.toc">
                  <span xmlns="" class="volume-value">Volume 106</span>
                  <span xmlns="" class="issue-value"> Issue 9</span></a></li>
            <li class="last">10.1093/jnci/dju203</li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/106/9/dju203.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view " itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Aiko+Nagayama&amp;sortspec=date&amp;submit=Submit">Aiko Nagayama</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Tetsu+Hayashida&amp;sortspec=date&amp;submit=Submit">Tetsu Hayashida</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Hiromitsu+Jinno&amp;sortspec=date&amp;submit=Submit">Hiromitsu Jinno</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Maiko+Takahashi&amp;sortspec=date&amp;submit=Submit">Maiko Takahashi</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Tomoko+Seki&amp;sortspec=date&amp;submit=Submit">Tomoko Seki</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Akiko+Matsumoto&amp;sortspec=date&amp;submit=Submit">Akiko Matsumoto</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Takeshi+Murata&amp;sortspec=date&amp;submit=Submit">Takeshi Murata</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Hutan+Ashrafian&amp;sortspec=date&amp;submit=Submit">Hutan Ashrafian</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Thanos+Athanasiou&amp;sortspec=date&amp;submit=Submit">Thanos Athanasiou</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Koji+Okabayashi&amp;sortspec=date&amp;submit=Submit">Koji Okabayashi</a></span> and 
                     </li>
                     <li class="last" id="contrib-11"><span class="name"><a class="name-search"
                              href="/search?author1=Yuko+Kitagawa&amp;sortspec=date&amp;submit=Submit">Yuko Kitagawa</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address>
                           <strong>Affiliations of authors:</strong> <span class="institution">Department of Surgery, Keio University School of Medicine</span>, <span class="addr-line">Tokyo</span>, Japan (AN, TH, HJ, MT, TS, AM, TM, KO, YK); <span class="institution">Department of Surgery and Cancer, Imperial College London</span>, <span class="addr-line">London</span>, UK (HA, TA).
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="corresp" id="corresp-1">
                        <strong>Correspondence to:</strong><br /> Tetsu Hayashida, MD, PhD, or Koji Okabayashi, MD, PhD, Department of Surgery, School of Medicine, Keio University, 35 Shinamo-machi,
                        Shinjuku, Tokyo 160–8582, Japan (e-mails: <span class="em-link"><span class="em-addr">tetsu{at}z7.keio.jp</span></span> and <span class="em-link"><span class="em-addr">okabayashikoji{at}gmail.com</span></span>, respectively).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2013-06-18"><span class="received-label">Received </span>June 18, 2013.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2014-05-13"><span class="rev-recd-label">Revision received </span>May 13, 2014.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2014-06-02"><span class="accepted-label">Accepted </span>June 2, 2014.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-5" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> The growing number of antihuman epidermal growth factor receptor-2 (HER2) agents suggests the need for defining the optimal
                        choice of neoadjuvant therapy for HER2-positive breast cancer. This study aims to assess the efficacy and safety of neoadjuvant
                        therapy for HER2-positive breast cancer.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection methods">
                     <p id="p-2"><strong>Methods</strong> Randomized trials that compared different anti-HER2 regimens in the neoadjuvant setting were included. The odds ratio (OR)
                        for pathological complete response (pCR), treatment completion, and safety was utilized for pooling effect sizes. Network
                        meta-analysis using a Bayesian statistical model was performed to combine the direct and indirect evidence of neoadjuvant
                        therapy for HER2-positive breast cancer. All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> A database search identified 1047 articles, with 10 studies meeting the eligibility criteria. A total of 2247 patients in
                        seven different treatment arms were assessed. Anti-HER2 agents evaluated included trastuzumab (tzmb), lapatinib (lpnb), and
                        pertuzumab (pzmb). Network meta-analysis showed no statistically significant difference between dual targeting treatment arms;
                        however, lpnb reduced treatment completion due to adverse events. Patients in dual targeting arms had statistically significantly
                        more pCR than those in other treatment arms (chemotherapy [CT] + tzmb + pzmb vs CT + tzmb, OR = 2.29, 95% credibility interval
                        = 1.02 to 5.02, <em>P</em> = .02). The surface under the cumulative ranking probability curve indicated that CT + tzmb + pzmb had the highest probability
                        of being the best treatment arm in terms of pCR.
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions</strong> This study indicates that combining two anti-HER2 agents with CT is the most effective treatment modality in the neoadjuvant
                        setting for HER2-positive breast cancer.
                     </p>
                  </div>
               </div>
               <p id="p-5">Overexpression or amplification of human epidermal growth factor receptor-2 (HER2) occurs in approximately 20% of human breast
                  cancers and has been traditionally associated with poor prognosis (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). Trastuzumab (tzmb), an anti-HER2 agent, has demonstrated clinically significant efficacy against HER2-positive breast cancer
                  and is considered the standard of care for adjuvant and metastatic treatment (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>). In a recent meta-analysis, the addition of tzmb to neoadjuvant chemotherapy (CT) also improved the probability of achieving
                  pathologically complete response (pCR) for HER2-positive breast cancer (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>).
               </p>
               <p id="p-6" class="indent">Positive efficacy outcomes with tzmb prompted the search to identify other HER2-targeted drugs capable of improving the therapeutic
                  effects of tzmb in combination or sequential administration (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>). The addition of the tyrosine kinase inhibitor lapatinib (lpnb) or monoclonal antibody pertuzumab (pzmb) to tzmb statistically
                  significantly improved progression-free survival (PFS) compared with tzmb alone in HER2-positive metastatic breast cancer
                  (MBC) (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>). In addition, other anti-HER2 agents are at varying stages of clinical development (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>). For example, an antibody-drug conjugate trastuzumab-DM1 (T-DM1) showed statistically significantly better PFS as compared
                  with lpnb plus capecitabine among patients with HER2-positive MBC (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>). Moreover, neratinib, a pan-HER tyrosine kinase inhibitor that irreversibly inhibits HER1 and HER2, has also shown activity
                  against MBC (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>).
               </p>
               <p id="p-7" class="indent">The growing number of HER2-targeted agents has created the need to define the optimal neoadjuvant therapy for HER2-positive
                  breast cancer. Although many trials have been conducted to compare treatments, it is difficult to integrate information on
                  the relative efficacy of all tested regimens, since each trial has compared only a few treatments. Recently, a promising but
                  much-debated extension of systematic reviews, network meta-analysis, has become increasingly popular. Network meta-analysis
                  synthesizes information from a network of trials and combines direct and indirect evidence on the relative effectiveness of
                  the treatments. For example, direct evidence comes from trials of A vs B, while indirect evidence, through an “intermediate”
                  comparator C, comes by combining trials of A vs C and of C vs B. This method helps interpret the randomized evidence from
                  a networks of trials and can rank many different treatments, going beyond the classical focus on simple direct comparisons
                  (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11–13</a>). This network meta-analysis has become widely employed, with the increased complexity of analyses that underpin clinical
                  guidelines and can serve decision-making for policy makers (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>). Here, we systematically assess the efficacy and safety of neoadjuvant therapy for HER2-positive breast cancer by conducting
                  direct and indirect comparisons from multiple randomized clinical trials.
               </p>
               <div class="section methods" id="sec-5">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-11" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Methods</h2>
                  <div id="sec-6" class="subsection">
                     <h3>Search Strategy</h3>
                     <p id="p-8">Searches were performed using MEDLINE and the Cochrane Central Register of Controlled Trials without year and language restrictions,
                        using the following search algorithm: Breast Neoplasms AND Neoadjuvant therapy AND Antibodies, Monoclonal OR Receptor, erbB-2.
                        The last search was updated in August 2012. Because recent trials with anti-HER2 agents in a neoadjuvant setting may still
                        be unpublished, electronic searches were also performed using the major international congress proceedings (American Society
                        of Clinical Oncology Annual Meeting and San Antonio Breast Cancer Symposium). In addition, the reference lists of all studies
                        fulfilling the eligibility criteria were examined for other relevant articles missed by the electronic searches.
                     </p>
                  </div>
                  <div id="sec-7" class="subsection">
                     <h3>Selection Criteria</h3>
                     <p id="p-9">Eligibility and exclusion criteria were prespecified. All randomized trials that compared at least two arms of different treatment
                        regimens involving CT and/or anti-HER2 agents in patients with HER2-positive breast cancer in the neoadjuvant setting were
                        considered. All cytotoxic CT regimens were considered eligible for the meta-analysis. If multiple publications of the same
                        trial were retrieved or if there was a case mix between publications, only the most recent and informative publication was
                        included. Using the Cochrane Collaboration risk of bias tool (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>), two independent reviewers (AN and TH) assessed all studies for quality; appropriateness of allocation, blinding, and management
                        of incomplete outcome data; and the completeness of reporting of outcomes.
                     </p>
                  </div>
                  <div id="sec-8" class="subsection">
                     <h3>Data Extraction</h3>
                     <p id="p-10">Data was extracted independently by two authors (AN and TH) according to a prespecified protocol, and a consensus was reached
                        on all items. From each eligible trial, the first author, year of publication, journal, country of origin as noted in their
                        affiliations, sample size, age, estrogen receptor/progesterone receptor status, node positivity, CT regimens, and anti-HER2
                        agent(s) dose/duration were recorded. Primary and secondary outcome measures were also recorded. Authors were contacted to
                        obtain missing data. If no response was received, analysis was performed without these data.
                     </p>
                  </div>
                  <div id="sec-9" class="subsection">
                     <h3>Definition of Outcomes</h3>
                     <p id="p-11">The primary outcome in this study was the number of patients who achieved pCR with the number of patients treated. pCR was
                        defined as no invasive residual cancer in the breast tissue and nodes; noninvasive breast residuals were allowed. Other definitions
                        of pCR were substituted if not reported. Secondary objectives were the number of patients who completed the treatment as planned
                        and the number of patients who had grade 3 or 4 adverse events, including diarrhea, neutropenia, and skin disorders, each
                        with the number of patients treated. Adverse events were graded according to National Cancer Institute Common Terminology
                        Criteria (NCI-CTC) version 4.0. If adverse events were not graded with the NCI-CTC, the corresponding numbers of the adverse
                        events were used. Cardiac events, including asymptomatic events, such as left ventricular ejection fraction less than 50%
                        or a drop of at least 10% from baseline, and symptomatic events, such as congestive heart failure or cardiac deaths, were
                        reported separately. However, outcomes, such as overall survival and disease-free survival (DFS), were not analyzed because
                        of insufficient data accumulation.
                     </p>
                  </div>
                  <div id="sec-10" class="subsection">
                     <h3>Statistical Methods</h3>
                     <p id="p-12">In direct comparisons, the odds ratio (OR) was utilized for pooling effect sizes, because all of the outcomes of interest
                        were dichotomous variables. Data was pooled using the DerSimonian-Laird random effects model (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>). Results were reported with 95% confidence intervals (CIs), and statistical significance was defined as <em>P</em> less than .05. All statistical tests were two-sided. If a direct comparison was based on two or more studies, statistical
                        heterogeneity was calculated using the <em>I</em>
                        <sup><em>2</em></sup> statistic. <em>I</em>
                        <sup><em>2</em></sup> describes the percentage of total variation across studies that is due to heterogeneity rather than chance (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). <em>I</em>
                        <sup><em>2</em></sup> quantifies the effect of heterogeneity in the studies’ results (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>). Furthermore, we defined the range: values above 50% indicative of large between-study heterogeneity, values of 25–50% indicative
                        of modest heterogeneity, and values below 25% indicative of low heterogeneity (<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>).
                     </p>
                     <p id="p-13" class="indent">Network meta-analysis using a Bayesian statistical model was carried out to compare the direct and indirect evidence for HER2-positive
                        breast cancer neoadjuvant therapy by combining all the information regarding efficacy, treatment completion, and adverse events
                        from different studies. The model applied to analyze the data is a Bayesian consistency model as described in Caldwell et
                        al. (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>). In a Bayesian framework, all parameters are treated as random variables. For each parameter of interest, its posterior
                        distribution is being estimated using Markov chain Monte Carlo by placing suitable prior distributions (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). A hierarchical Bayesian model is a natural extension of a meta-analysis model for synthesizing comparisons between treatment
                        pairs (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). Multivariate meta-analysis provides a solution to the multiplicity problem by summarizing simultaneously all outcomes of
                        interest instead of conducting many separate univariate meta-analyses. A common heterogeneity parameter <em>τ</em>
                        <sup><em>2</em></sup> was assumed across all comparisons using a random effects model within a Bayesian statistical model. Effect sizes were presented
                        along with 95% credibility intervals (CrIs). When combining the results of direct and indirect comparisons, the extent to
                        which these results are inconsistent (in disagreement) with each other was examined. In a network of treatments, different
                        direct comparisons form evidence cycles, also called loops, within which inconsistency is evaluated (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>). In addition, Bayesian network meta-analysis provides a ranking probability curve of each treatment (rankogram) by calculating
                        the probability of each arm to achieve the best rank among all. A simple numerical summary to supplement the graphical display
                        of cumulative ranking is to estimate the surface under the cumulative ranking (SUCRA) line for each treatment; SUCRA would
                        be one when a treatment is certain to be the best and zero when a treatment is certain to be the worst (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>).
                     </p>
                     <p id="p-14" class="indent">Direct comparisons and risk of bias assessment were calculated by Review Manager (RevMan), Version 5.1 (The Nordic Cochrane
                        Centre: The Cochrane Collaboration, Copenhagen, Norway). Bayesian network meta-analyses and the node-splitting method were
                        calculated by WinBUGS version 1.4 (MRC Biostatistics Unit, Cambridge, UK). Odds ratio, heterogeneity, and inconsistency were
                        calculated, and diagrams were made by R version 2.13.2 (R Project for Statistical Computing, Vienna, Austria). The reporting
                        of this meta-analysis is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
                        (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>).
                     </p>
                  </div>
               </div>
               <div class="section" id="sec-11">
                  <div class="section-nav"><a href="#sec-5" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-13" title="Results of Direct Comparisons" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Results</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Overview of Literature Search and Study Characteristics</h3>
                     <p id="p-15">An electronic database search identified 1047 articles. Of these, 19 potentially eligible articles were evaluated in more
                        detail, and 10 studies were found that met the eligibility criteria for this study (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a> and <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>). A total of 2247 patients in seven different treatment arms were assessed: CT alone; CT with tzmb, lpnb, or pzmb; tzmb and
                        pzmb; CT with tzmb and lpnb; and CT with tzmb and pzmb. The Neosphere (<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>), NeoALTTO (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>), and CHER-LOB (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>) studies incorporated a treatment arm of dual anti-HER2 agents. Anti-HER2 agents were administered concomitantly with CT
                        in all studies except for the NeoALTTO study, in which anti-HER2 agent alone was given for the first six weeks (<a id="xref-ref-24-2" class="xref-bibr" href="#ref-24">24</a>). The majority of neoadjuvant CT regimens that were chosen comprised anthracyclines and taxanes. Across the 10 studies, hormone-receptor
                        (HR)–positive tumors accounted for 34–61%. The other risks of bias for each of the included studies were assessed in <a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/dju203/-/DC1">Supplementary Table 1</a> (available online).
                     </p>
                     <div id="T1" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="dju203/T1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="dju203/T1.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 1.</span> 
                           <p id="p-16" class="first-child">Characteristics of eligible studies*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F1" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="dju203/F1.expansion.html"><img alt="Figure 1." src="dju203/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="dju203/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="dju203/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/106/9/dju203/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 1.</span> 
                           <p id="p-18" class="first-child">CONSORT diagram of study selection. RCT = randomized controlled trial.</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section" id="sec-13">
                  <div class="section-nav"><a href="#sec-11" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Results of Direct Comparisons</h2>
                  <p id="p-19">From the eligible studies, 10 direct comparisons were made (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2</a>).
                  </p>
                  <div id="F2" class="fig pos-float type-figure  odd">
                     <div class="fig-inline"><a href="dju203/F2.expansion.html"><img alt="Figure 2." src="dju203/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="dju203/F2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="dju203/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/106/9/dju203/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label">Figure 2.</span> 
                        <p id="p-20" class="first-child">Network diagram of studies comparing pathological complete response (pCR) of different neoadjuvant therapies for human epidermal
                           growth factor receptor-2-positive breast cancer. Each link represents at least 1 study and the widths of each link are proportional
                           to the number of studies comparing the particular arms. The size of each node is proportional to the total sample size. CT
                           = chemotherapy; lpnb = lapatinib; pzmb = pertuzumab; tzmb = trastuzumab.
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <p id="p-21">CT vs CT + tzmb (<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26–30</a>)
                  </p>
                  <p id="p-22">CT + lpnb vs CT + tzmb (<a id="xref-ref-24-3" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>)
                  </p>
                  <p id="p-23">CT + pzmb vs CT + tzmb (<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-24">Tzmb + pzmb vs CT + tzmb (<a id="xref-ref-23-3" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-25">CT + tzmb + lpnb vs CT + tzmb (<a id="xref-ref-24-4" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-25-3" class="xref-bibr" href="#ref-25">25</a>)
                  </p>
                  <p id="p-26">CT + tzmb + pzmb vs CT + tzmb (<a id="xref-ref-23-4" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-27">CT + tzmb + lpnb vs CT + lpnb (<a id="xref-ref-24-5" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-25-4" class="xref-bibr" href="#ref-25">25</a>)
                  </p>
                  <p id="p-28">Tzmb + pzmb vs CT + pzmb (<a id="xref-ref-23-5" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-29">CT + tzmb + pzmb vs CT + pzmb (<a id="xref-ref-23-6" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-30">CT + tzmb + pzmb vs tzmb + pzmb (<a id="xref-ref-23-7" class="xref-bibr" href="#ref-23">23</a>)
                  </p>
                  <p id="p-31" class="indent">Among the 10 studies, five comparisons included pzmb and were based on one study (<a id="xref-ref-23-8" class="xref-bibr" href="#ref-23">23</a>).
                  </p>
                  <p id="p-32" class="indent">The number of patients who achieved pCR was reported in 10 studies. The number of patients who completed the treatment as
                     planned was reported in six studies (<a id="xref-ref-23-9" class="xref-bibr" href="#ref-23">23–26</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-32-2" class="xref-bibr" href="#ref-32">32</a>). Diarrhea was reported in eight studies (<a id="xref-ref-23-10" class="xref-bibr" href="#ref-23">23–25</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28–32</a>), in which seven of these studies (<a id="xref-ref-23-11" class="xref-bibr" href="#ref-23">23–25</a>,<a id="xref-ref-29-2" class="xref-bibr" href="#ref-29">29–32</a>) reported grade 3 and 4 events based on NCI-CTC. Neutropenia was reported in eight studies (<a id="xref-ref-23-12" class="xref-bibr" href="#ref-23">23–26</a>,<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28–30</a>,<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32">32</a>), in which six of these studies (<a id="xref-ref-23-13" class="xref-bibr" href="#ref-23">23–25</a>,<a id="xref-ref-29-3" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-4" class="xref-bibr" href="#ref-32">32</a>) reported grade 3 and 4 events. Cardiac events were reported in eight studies (<a id="xref-ref-23-14" class="xref-bibr" href="#ref-23">23–29</a>,<a id="xref-ref-32-5" class="xref-bibr" href="#ref-32">32</a>). Skin disorder was reported in six studies (<a id="xref-ref-23-15" class="xref-bibr" href="#ref-23">23–25</a>,<a id="xref-ref-28-3" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-30-2" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-6" class="xref-bibr" href="#ref-32">32</a>), in which five of these studies (<a id="xref-ref-23-16" class="xref-bibr" href="#ref-23">23–25</a>,<a id="xref-ref-30-3" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-7" class="xref-bibr" href="#ref-32">32</a>) reported grade 3 and 4. <a id="xref-fig-2-2" class="xref-fig" href="#F2">Figure 2</a> demonstrates the network diagram of eligible comparisons for pCR. The most commonly studied head-to-head comparison was CT
                     vs CT + tzmb. The treatment effect of direct comparisons in forest plots is shown in <a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/dju203/-/DC1">Supplementary Figure 1, A-D</a> (available online).
                  </p>
                  <p id="p-33" class="indent">Odds ratio and heterogeneity by <em>I</em>
                     <sup><em>2</em></sup> statistics for all direct comparisons are listed in <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>. The result showed a statistically significantly higher incidence of pCR in treatment arms of dual anti-HER2 agents with
                     CT than in other arms. Although no statistically significant difference was found among treatment arms of a single anti-HER2
                     agent with CT, CT + lpnb was associated with inferior efficacy compared with CT + tzmb. Lpnb-containing treatment arms showed
                     statistically significantly less treatment completion with more incidence of diarrhea and skin disorder compared with CT +
                     tzmb. Tzmb + pzmb had statistically significantly less incidence of neutropenia compared with CT-containing arms. The incidence
                     of cardiac events did not show any statistically significant difference among all the treatment arms. Across all the studies,
                     seven patients were reported to have symptomatic congestive heart failure, although no cardiac death was reported in the eligible
                     studies. An estimate consistent with large heterogeneity (<em>I</em>
                     <sup><em>2</em></sup> &gt; 50%) was seen in seven comparisons, while no large heterogeneity was seen in comparisons concerning pCR.
                  </p>
                  <div id="T2" class="table pos-float">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="dju203/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="dju203/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 2.</span> 
                        <p id="p-34" class="first-child">The odds ratios and heterogeneity for direct comparisons*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Bayesian Network Meta-Analysis</h3>
                     <p id="p-39">From the eligible studies, 21 indirect comparisons were made. Results of all possible comparisons were expressed with odds
                        ratio and credibility interval calculated by Bayesian network meta-analysis (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). Twelve statistically significant differences were found in pCR, two in treatment completion, 10 in diarrhea, six in neutropenia,
                        four in skin disorder, and none in cardiac events. These results demonstrated that dual anti-HER2 agents with CT had a statistically
                        significantly higher incidence of pCR than CT + tzmb (CT + tzmb + pzmb vs CT + tzmb, OR = 2.29, 95% credibility interval =
                        1.02 to 5.02, <em>P</em> = .02), whereas CT and CT + lpnb had a statistically significantly lower incidence of pCR compared with CT + tzmb. This finding
                        strengthened the results of the direct comparisons. In particular, CT + tzmb + pzmb did not show any statistically significant
                        difference in pCR compared to CT + tzmb + lpnb. Again, lpnb-containing treatment arms showed statistically significantly less
                        treatment completion and more diarrhea and skin disorder compared with CT + tzmb.
                     </p>
                     <div id="T3" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="dju203/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="dju203/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3.</span> 
                           <p id="p-40" class="first-child">The odds ratio and 95% credibility intervals calculated by Bayesian network meta-analysis*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-44" class="indent">Analysis of inconsistency between direct and indirect comparisons indicated that a statistically significant inconsistency
                        was identified in pCR, treatment completion, diarrhea, and neutropenia, but not in cardiac events and skin disorder. However,
                        clinical variables that may affect these inconsistencies could not be identified in this study (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/dju203/-/DC1">Supplementary Figure 2</a>, available online).
                     </p>
                  </div>
                  <div id="sec-15" class="subsection">
                     <h3>Ranking of Treatment Arms</h3>
                     <p id="p-45">Values of SUCRA (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3</a>) indicated that CT + tzmb + pzmb had the highest probability of being the best treatment arm for pCR (SUCRA = 0.93), followed
                        by CT + tzmb + lpnb (SUCRA = 0.90), and CT + tzmb (SUCRA = 0.62). In contrast, CT alone had the lowest probability. CT + tzmb
                        had the best result for treatment completion and the second best for diarrhea. Lpnb-containing arms had a low probability
                        of being the best in terms of treatment completion, diarrhea, neutropenia, and skin disorder. The probability of each treatment
                        achieving the largest number of patients with pCR is shown in <a id="xref-fig-4-1" class="xref-fig" href="#F4">Figure 4</a>. This analysis indicated that CT + tzmb + pzmb was most probable to be the rank 1 (57.5%), CT +tzmb + lpnb to be the rank
                        2 (54.4%), CT + tzmb to be the rank 3 (71.1%), CT + pzmb to be the rank 4 (44.4%), CT + lpnb to be the rank 5 (46.6%), tzmb
                        + pzmb to be the rank 6 (37.3%), and CT to be the rank 7 (63.6%).
                     </p>
                     <div id="F3" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="dju203/F3.expansion.html"><img alt="Figure 3." src="dju203/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="dju203/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="dju203/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/106/9/dju203/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 3.</span> 
                           <p id="p-46" class="first-child">Heat map graph of overall efficacy according to surface under the cumulative ranking probability curve (SUCRA). Comparative
                              strengths and limitations of each treatment arm. The <strong>green color</strong> indicates higher SUCRA values with greater probability to be the best treatment arm (more pathological complete response
                              [pCR], treatment completion, and fewer adverse events), and the red color indicates lower SUCRA values with lower probability
                              to be the best treatment arm (less pCR, treatment completion, and more adverse events). The SUCRA values are shown in each
                              box. Chemotherapy (CT) + trastuzumab (tzmb) + lapatinib (lpnb) and CT + tzmb + pertuzumab (pzmb) are the most effective treatment
                              arms. CT + tzmb had the best result for treatment completion and the second best for diarrhea. Lpnb-containing treatment arms
                              have lower SUCRA values for treatment completion, diarrhea, neutropenia, and skin disorder than other treatment arms, whereas
                              tzmb + pzmb has high SUCRA values for diarrhea, neutropenia, and skin disorder. All statistical tests were two-sided.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F4" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="dju203/F4.expansion.html"><img alt="Figure 4." src="dju203/F4.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="dju203/F4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="dju203/F4.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/106/9/dju203/F4">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 4.</span> 
                           <p id="p-47" class="first-child">Ranking for pathological complete response (pCR). Each value represents the probability of each treatment to be a specific
                              rank. The <strong>blue balloon area</strong> is proportional to the probability. For example, the probability of chemotherapy (CT) + trastuzumab (tzmb) + pertuzumab (pzmb)
                              to have the largest number of patients with pCR among all treatments is 57.5%, and the probability of CT to have the smallest
                              number of patients with pCR is 63.6%. All statistical tests were two-sided. lpnb = lapatinib.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section" id="sec-16">
                  <div class="section-nav"><a href="#sec-13" title="Results of Direct Comparisons" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-17" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Discussion</h2>
                  <p id="p-48">The concept of dual targeting therapy of HER2-positive breast cancer was introduced based on preclinical studies that showed
                     primary and acquired resistance to anti-HER2 agents, their nonoverlapping mechanisms of action, and their synergistic interaction
                     (<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>). Our meta-analysis also showed that patients in the dual targeting therapy arms, CT + tzmb + lpnb and CT + tzmb + pzmb,
                     achieved statistically significantly more pCR than other treatment arms from the best available evidence.
                  </p>
                  <p id="p-49" class="indent">This promising result of dual targeting therapy will lead us to the argument about whether the dual targeting therapy should
                     be used in a neoadjuvant setting, adjuvant setting, or metastatic setting to have the best outcome as a whole. More insight
                     was gained on how to predict long-term outcome by assessing the tumor response to neoadjuvant therapy. In HER2-positive and
                     triple-negative breast cancer, pCR is more highly predictive of DFS within every established receptor subset than overall,
                     demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology (<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>). Survival analysis of the NOAH study showed a strong correlation between pCR and improved event-free survival (<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>). Meanwhile, a recent pooled analysis of the German neoadjuvant studies showed a statistically significant difference in
                     DFS between pCR and no pCR among patients with HER2-positive/HR-negative tumors (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>), indicating a hypothesis that neoadjuvant dual HER2 blockade is expected to improve DFS in this subset. In contrast, pCR
                     was not associated with a statistically significantly better DFS compared with no pCR among patients with HER2-positive/HR-positive
                     tumors. This conflicting result indicates that data regarding pCR should be interpreted with caution, especially in HER2-positive/HR-positive
                     tumors, unless other data sets provide substantial evidence.
                  </p>
                  <p id="p-50" class="indent">Although the pCRs in two different dual targeting therapies, CT + tzmb + lpnb and CT + tzmb + pzmb, were indistinguishable
                     when compared indirectly in this study, treatment completion and safety were inferior in the CT + tzmb + lpnb group. Since
                     lpnb-containing arms presented the disadvantage of less treatment completion, more diarrhea and skin disorder, patients treated
                     with CT + tzmb + pzmb are expected to benefit from continued treatment and safety. The incidence of cardiac events did not
                     increase in patients treated with dual targeting therapies. In regards to safety, CT + tzmb had the best result for treatment
                     completion and the second best for diarrhea from our SUCRA analysis. Therefore, CT + tzmb therapy may remain as one of the
                     options of neoadjuvant therapy for HER2-positive breast cancer, particularly considering the rising cost of targeted therapies
                     and limited medical resources. A unique treatment arm without a chemotherapy partner, tzmb + pzmb, demonstrated remarkable
                     safety in our study. However, tzmb + pzmb is not recommended as neoadjuvant therapy because pCR in the tzmb + pzmb arm was
                     statistically significantly inferior compared with CT + tzmb.
                  </p>
                  <p id="p-51" class="indent">This study provides insight into the best HER2-targeted therapies for HER2-positive breast cancer; however, it does have some
                     limitations. First, the number of studies and the number of patients included are relatively small. In particular, the informative
                     value of the direct comparisons of the pzmb-containing arms was limited by the low number of events in small study populations.
                     For some treatment comparisons in the examined network, no direct evidence was available, and thus evaluation of inconsistency
                     (ie, the extent of disagreement between direct and indirect evidence) was impossible. Second, given the retrospective nature
                     of the meta-analysis, publication bias and selective reporting biases cannot be excluded. Although such biases may affect
                     sporadic comparisons, they are unlikely to refute the overall result. Third, the patient populations vary across studies,
                     which may cause the heterogeneity of our analysis. Finally, an important consideration is that this study only analyzes pCR
                     and treatment completion as an efficacy, and future study needs separate confirmation of the surrogacy relation of pCR with
                     survival data.
                  </p>
                  <p id="p-52" class="indent">In conclusion, our study, with randomized data regarding three different anti-HER2 agents (tzmb, lpnb, and pzmb), provides
                     evidence that neoadjuvant dual targeting using anti-HER2 agents with CT shows a statistically significantly larger number
                     of patients with pCR than CT alone, single targeting with CT, and dual targeting without CT for HER2-positive breast cancer.
                  </p>
               </div>
               <div class="section" id="sec-17">
                  <div class="section-nav"><a href="#sec-16" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#notes-1" title="Notes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Funding</h2>
                  <p id="p-53">This work was supported by the Ministry of Education, Culture, Sports, <span class="funding-source">Science and Technology of Japan Grants-in-Aid for Scientific Research</span> (Grant NOs. <span class="award-id" id="award-id-1">#25293292</span>, <span class="award-id" id="award-id-2">#25461997</span>, and <span class="award-id" id="award-id-3">#25861163</span>).
                  </p>
               </div>
               <div class="section notes" id="notes-1">
                  <div class="section-nav"><a href="#sec-17" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Notes</h2>
                  <p id="p-54">The study sponsors had no role in the design of the study, the collection, analysis, or interpretation of the data, the writing
                     of the manuscript, nor the decision to submit the manuscript for publication. A. Nagayama owns stock options of Chugai, Inc.
                     A. Nagayama’s immediate family member has a leadership position with Chugai, Inc. and Roche, Inc. Y. Kitagawa received research
                     grants and lecture fees from Chugai, Inc. T. Hayashida received lecture fees from Chugai, Inc. H. Jinno received research
                     grants and lecture fees from Chugai, Inc. and GSK, Inc. We thank Toshimi Takano, MD, in Toranomon Hospital, for critical reading.
                  </p>
               </div>
               <ul class="copyright-statement">
                  <li class="fn" id="copyright-statement-1">© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#notes-1" title="Notes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2 class="">References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.1"
                             data-doi="10.1634/theoncologist.2008-0230">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ross</span>  <span class="cit-name-given-names">JS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Slodkowska</span>  <span class="cit-name-given-names">EA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Symmans</span>  <span class="cit-name-given-names">WF</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine</span>. <abbr class="cit-jnl-abbrev">Oncologist</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">14</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">320</span>–<span class="cit-lpage">368</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=theoncologist&amp;resid=14/4/320"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.2"
                             data-doi="10.1186/1471-2407-7-153">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Viani</span>  <span class="cit-name-given-names">GA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Afonso</span>  <span class="cit-name-given-names">SL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stefano</span>  <span class="cit-name-given-names">EJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials</span>. <abbr class="cit-jnl-abbrev">BMC Cancer</abbr>. <span class="cit-pub-date">2007</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">153</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1471-2407-7-153&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17686164&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20trastuzumab%20in%20the%20treatment%20of%20her-2-positive%20early%20breast%20cancer%3A%20a%20meta-analysis%20of%20published%20randomized%20trials&amp;author=GA%20Viani&amp;author=SL%20Afonso&amp;author=EJ%20Stefano&amp;publication_year=2007&amp;journal=BMC%20Cancer&amp;volume=7&amp;pages=153">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text"
                           id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.3"
                             data-doi="10.1093/annonc/mdq593">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Harris</span>  <span class="cit-name-given-names">CA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ward</span>  <span class="cit-name-given-names">RL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dobbins</span>  <span class="cit-name-given-names">TA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">22</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">1308</span>–<span class="cit-lpage">1317</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=22/6/1308"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text"
                           id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.4"
                             data-doi="10.1016/j.breast.2011.06.009">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valachis</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mauri</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Polyzos</span>  <span class="cit-name-given-names">NP</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis</span>. <abbr class="cit-jnl-abbrev">Breast</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">20</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">485</span>–<span class="cit-lpage">490</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.breast.2011.06.009&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=21784637&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000298531700001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Trastuzumab%20combined%20to%20neoadjuvant%20chemotherapy%20in%20patients%20with%20HER2-positive%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis&amp;author=A%20Valachis&amp;author=D%20Mauri&amp;author=NP%20Polyzos&amp;publication_year=2011&amp;journal=Breast&amp;volume=20&amp;issue=6&amp;pages=485-490">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.5"
                             data-doi="10.1158/1078-0432.CCR-09-1947">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Abramson</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Arteaga</span>  <span class="cit-name-given-names">CL</span></span></li>
                              </ol><cite>. <span class="cit-article-title">New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">17</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">952</span>–<span class="cit-lpage">958</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=17/5/952"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.6"
                             data-doi="10.1200/JCO.2008.21.4437">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blackwell</span>  <span class="cit-name-given-names">KL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Burstein</span>  <span class="cit-name-given-names">HJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Storniolo</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory
                                    metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1124</span>–<span class="cit-lpage">1130</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=28/7/1124"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.7"
                             data-doi="10.1056/NEJMoa1113216">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baselga</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cortes</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kim</span>  <span class="cit-name-given-names">SB</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">366</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">109</span>–<span class="cit-lpage">119</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1113216&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22149875&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000298985000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Pertuzumab%20plus%20trastuzumab%20plus%20docetaxel%20for%20metastatic%20breast%20cancer&amp;author=J%20Baselga&amp;author=J%20Cortes&amp;author=SB%20Kim&amp;publication_year=2012&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;issue=2&amp;pages=109-119">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.8"
                             data-doi="10.1097/CAD.0b013e328352d292">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Murphy</span>  <span class="cit-name-given-names">CG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Morris</span>  <span class="cit-name-given-names">PG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Recent advances in novel targeted therapies for HER2-positive breast cancer</span>. <abbr class="cit-jnl-abbrev">Anticancer Drugs</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">23</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">765</span>–<span class="cit-lpage">776</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/CAD.0b013e328352d292&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22824822&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Recent%20advances%20in%20novel%20targeted%20therapies%20for%20HER2-positive%20breast%20cancer&amp;author=CG%20Murphy&amp;author=PG%20Morris&amp;publication_year=2012&amp;journal=Anticancer%20Drugs&amp;volume=23&amp;issue=8&amp;pages=765-776">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.9"
                             data-doi="10.1056/NEJMoa1209124">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Verma</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miles</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gianni</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Trastuzumab emtansine for HER2-positive advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">367</span>(<span class="cit-issue">19</span>):<span class="cit-fpage">1783</span>–<span class="cit-lpage">1791</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1209124&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=23020162&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000310773200005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Trastuzumab%20emtansine%20for%20HER2-positive%20advanced%20breast%20cancer&amp;author=S%20Verma&amp;author=D%20Miles&amp;author=L%20Gianni&amp;publication_year=2012&amp;journal=N%20Engl%20J%20Med&amp;volume=367&amp;issue=19&amp;pages=1783-1791">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.10"
                             data-doi="10.1093/annonc/mds284">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Awada</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dirix</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Manso Sanchez</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast
                                    cancer pretreated with anti-HER2 therapy</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">24</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">109</span>–<span class="cit-lpage">116</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=24/1/109"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.11"
                             data-doi="10.1177/0962280207080643">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Salanti</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Evaluation of networks of randomized trials</span>. <abbr class="cit-jnl-abbrev">Stat Methods Med Res</abbr>. <span class="cit-pub-date">2008</span>;<span class="cit-vol">17</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">279</span>–<span class="cit-lpage">301</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spsmm&amp;resid=17/3/279"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.12"
                             data-doi="10.1136/bmj.331.7521.897">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Caldwell</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Simultaneous comparison of multiple treatments: combining direct and indirect evidence</span>. <abbr class="cit-jnl-abbrev">Bmj</abbr>. <span class="cit-pub-date">2005</span>;<span class="cit-vol">331</span>(<span class="cit-issue">7521</span>):<span class="cit-fpage">897</span>–<span class="cit-lpage">900</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=331/7521/897"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.13"
                             data-doi="10.1002/sim.1875">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lu</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination of direct and indirect evidence in mixed treatment comparisons</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr>. <span class="cit-pub-date">2004</span>;<span class="cit-vol">23</span>(<span class="cit-issue">20</span>):<span class="cit-fpage">3105</span>–<span class="cit-lpage">3124</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1875&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15449338&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224307300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20of%20direct%20and%20indirect%20evidence%20in%20mixed%20treatment%20comparisons&amp;author=G%20Lu&amp;author=AE%20Ades&amp;publication_year=2004&amp;journal=Stat%20Med&amp;volume=23&amp;issue=20&amp;pages=3105-3124">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.14"
                             data-doi="10.1017/S2045796011000084">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Barbui</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cipriani</span>  <span class="cit-name-given-names">A</span></span></li>
                              </ol><cite>. <span class="cit-article-title">What are evidence-based treatment recommendations?</span>
                                 <abbr class="cit-jnl-abbrev">Epidemiol Psychiatr Sci</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">20</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">29</span>–<span class="cit-lpage">31</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1017/S2045796011000084&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=21657112&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=What%20are%20evidence-based%20treatment%20recommendations%3F&amp;author=C%20Barbui&amp;author=A%20Cipriani&amp;publication_year=2011&amp;journal=Epidemiol%20Psychiatr%20Sci&amp;volume=20&amp;issue=1&amp;pages=29-31">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.15"
                             data-doi="10.1136/bmj.d5928">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Altman</span>  <span class="cit-name-given-names">DG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gotzsche</span>  <span class="cit-name-given-names">PC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials</span>. <abbr class="cit-jnl-abbrev">Bmj</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">343</span>:<span class="cit-fpage">d5928</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=343/oct18_2/d5928"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.16"
                             data-doi="10.1016/0197-2456(86)90046-2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">DerSimonian</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Laird</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis in clinical trials</span>. <abbr class="cit-jnl-abbrev">Control Clin Trials</abbr>. <span class="cit-pub-date">1986</span>;<span class="cit-vol">7</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">177</span>–<span class="cit-lpage">188</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(86)90046-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3802833&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F013900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20in%20clinical%20trials&amp;author=R%20DerSimonian&amp;author=N%20Laird&amp;publication_year=1986&amp;journal=Control%20Clin%20Trials&amp;volume=7&amp;issue=3&amp;pages=177-188">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.17"
                             data-doi="10.1136/bmj.327.7414.557">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thompson</span>  <span class="cit-name-given-names">SG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Deeks</span>  <span class="cit-name-given-names">JJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Measuring inconsistency in meta-analyses</span>. <abbr class="cit-jnl-abbrev">Bmj</abbr>. <span class="cit-pub-date">2003</span>;<span class="cit-vol">327</span>(<span class="cit-issue">7414</span>):<span class="cit-fpage">557</span>–<span class="cit-lpage">560</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=327/7414/557"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.18"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thompson</span>  <span class="cit-name-given-names">SG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Quantifying heterogeneity in a meta-analysis</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr>. <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1539</span>–<span class="cit-lpage">1558</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Quantifying%20heterogeneity%20in%20a%20meta-analysis&amp;author=JP%20Higgins&amp;author=SG%20Thompson&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;issue=11&amp;pages=1539-1558">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.19"
                             data-doi="10.1177/0962280211432219">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mavridis</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Salanti</span>  <span class="cit-name-given-names">G</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A practical introduction to multivariate meta-analysis</span>. <abbr class="cit-jnl-abbrev">Stat Methods Med Res</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">22</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">133</span>–<span class="cit-lpage">158</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spsmm&amp;resid=22/2/133"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.20"
                             data-doi="10.1093/ije/dys222">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Veroniki</span>  <span class="cit-name-given-names">AA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vasiliadis</span>  <span class="cit-name-given-names">HS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Evaluation of inconsistency in networks of interventions</span>. <abbr class="cit-jnl-abbrev">Int J Epidemiol</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">42</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">332</span>–<span class="cit-lpage">345</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=intjepid&amp;resid=42/1/332"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.21"
                             data-doi="10.1016/j.jclinepi.2010.03.016">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Salanti</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ioannidis</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial</span>. <abbr class="cit-jnl-abbrev">J Clin Epidemiol</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">64</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">163</span>–<span class="cit-lpage">171</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.jclinepi.2010.03.016&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20688472&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000287281300007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Graphical%20methods%20and%20numerical%20summaries%20for%20presenting%20results%20from%20multiple-treatment%20meta-analysis%3A%20an%20overview%20and%20tutorial&amp;author=G%20Salanti&amp;author=AE%20Ades&amp;author=JP%20Ioannidis&amp;publication_year=2011&amp;journal=J%20Clin%20Epidemiol&amp;volume=64&amp;issue=2&amp;pages=163-171">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text"
                           id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.22"
                             data-doi="10.1136/bmj.b2700">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Liberati</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Altman</span>  <span class="cit-name-given-names">DG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tetzlaff</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
                                    explanation and elaboration</span>. <abbr class="cit-jnl-abbrev">Bmj</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">339</span>:<span class="cit-fpage">b2700</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=339/jul21_1/b2700"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text"
                           id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.23"
                             data-doi="10.1016/S1470-2045(11)70336-9">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gianni</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pienkowski</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Im</span>  <span class="cit-name-given-names">YH</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive
                                    breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">25</span>–<span class="cit-lpage">32</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70336-9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22153890&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000299014500042&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20neoadjuvant%20pertuzumab%20and%20trastuzumab%20in%20women%20with%20locally%20advanced%2C%20inflammatory%2C%20or%20early%20HER2-positive%20breast%20cancer%20%28NeoSphere%29%3A%20a%20randomised%20multicentre%2C%20open-label%2C%20phase%202%20trial&amp;author=L%20Gianni&amp;author=T%20Pienkowski&amp;author=YH%20Im&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=1&amp;pages=25-32">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.24"
                             data-doi="10.1016/S0140-6736(11)61847-3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baselga</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bradbury</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Eidtmann</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase
                                    3 trial</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">379</span>(<span class="cit-issue">9816</span>):<span class="cit-fpage">633</span>–<span class="cit-lpage">640</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(11)61847-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22257673&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300629000034&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%20with%20trastuzumab%20for%20HER2-positive%20early%20breast%20cancer%20%28NeoALTTO%29%3A%20a%20randomised%2C%20open-label%2C%20multicentre%2C%20phase%203%20trial&amp;author=J%20Baselga&amp;author=I%20Bradbury&amp;author=H%20Eidtmann&amp;publication_year=2012&amp;journal=Lancet&amp;volume=379&amp;issue=9816&amp;pages=633-640">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">25.</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.25"
                             data-doi="10.1200/JCO.2011.39.0823">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Guarneri</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Frassoldati</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bottini</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable
                                    breast cancer: results of the randomized phase II CHER-LOB study</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">16</span>):<span class="cit-fpage">1989</span>–<span class="cit-lpage">1995</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/16/1989"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">26.</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26. in text"
                           id="ref-26">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.26"
                             data-doi="10.1158/1078-0432.CCR-06-1345">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buzdar</span>  <span class="cit-name-given-names">AU</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valero</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ibrahim</span>  <span class="cit-name-given-names">NK</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent
                                    trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized
                                    study population and data of additional patients treated with the same regimen</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2007</span>;<span class="cit-vol">13</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">228</span>–<span class="cit-lpage">233</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=13/1/228"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">27.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-106.9.dju203.27"
                             data-doi="10.1002/cncr.25309">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chang</span>  <span class="cit-name-given-names">HR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Glaspy</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Allison</span>  <span class="cit-name-given-names">MA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">116</span>(<span class="cit-issue">18</span>):<span class="cit-fpage">4227</span>–<span class="cit-lpage">4237</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.25309&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20549829&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000281507900006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Differential%20response%20of%20triple-negative%20breast%20cancer%20to%20a%20docetaxel%20and%20carboplatin-based%20neoadjuvant%20treatment&amp;author=HR%20Chang&amp;author=J%20Glaspy&amp;author=MA%20Allison&amp;publication_year=2010&amp;journal=Cancer&amp;volume=116&amp;issue=18&amp;pages=4227-4237">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">28.</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28. in text"
                           id="ref-28">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.28">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Steger</span>  <span class="cit-name-given-names">GG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Greil</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jakesz</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin
                                    and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as
                                    Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Res</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">69</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">564S</span>–<span class="cit-lpage">564S</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Final%20Results%20of%20ABCSG-24%2C%20a%20Randomized%20Phase%20III%20Study%20Comparing%20Epirubicin%2C%20Docetaxel%2C%20and%20Capecitabine%20%28EDC%29%20to%20Epirubicin%20and%20Docetaxel%20%28ED%29%20as%20Neoadjuvant%20Treatment%20for%20Early%20Breast%20Cancer%20and%20Comparing%20ED%2FEDC%20plus%20Trastuzumab%20%28T%29%20to%20ED%2FEDC%20as%20Neoadjuvant%20Treatment%20for%20Early%20HER-2%20Positive%20Breast%20Cancer&amp;author=GG%20Steger&amp;author=R%20Greil&amp;author=R%20Jakesz&amp;publication_year=2009&amp;journal=Cancer%20Res&amp;volume=69&amp;issue=24&amp;pages=564S-564S">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">29.</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29. in text"
                           id="ref-29">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.29"
                             data-doi="10.1016/j.ejso.2011.07.003">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Semiglazov</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Eiermann</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zambetti</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating
                                    in the NeOAdjuvant Herceptin (NOAH) study</span>. <abbr class="cit-jnl-abbrev">Eur J Surg Oncol</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">37</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">856</span>–<span class="cit-lpage">863</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.ejso.2011.07.003&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=21843921&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Surgery%20following%20neoadjuvant%20therapy%20in%20patients%20with%20HER2-positive%20locally%20advanced%20or%20inflammatory%20breast%20cancer%20participating%20in%20the%20NeOAdjuvant%20Herceptin%20%28NOAH%29%20study&amp;author=V%20Semiglazov&amp;author=W%20Eiermann&amp;author=M%20Zambetti&amp;publication_year=2011&amp;journal=Eur%20J%20Surg%20Oncol&amp;volume=37&amp;issue=10&amp;pages=856-863">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">30.</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30. in text"
                           id="ref-30">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.30"
                             data-doi="10.1007/s10549-010-0939-3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pierga</span>  <span class="cit-name-given-names">JY</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Delaloge</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Espie</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib
                                    or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">122</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">429</span>–<span class="cit-lpage">437</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s10549-010-0939-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20480225&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000278810700012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20multicenter%20randomized%20phase%20II%20study%20of%20sequential%20epirubicin%2Fcyclophosphamide%20followed%20by%20docetaxel%20with%20or%20without%20celecoxib%20or%20trastuzumab%20according%20to%20HER2%20status%2C%20as%20primary%20chemotherapy%20for%20localized%20invasive%20breast%20cancer%20patients&amp;author=JY%20Pierga&amp;author=S%20Delaloge&amp;author=M%20Espie&amp;publication_year=2010&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=122&amp;issue=2&amp;pages=429-437">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">31.</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31. in text"
                           id="ref-31">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.31">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Alba</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Albanell</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Haba</span>  <span class="cit-name-given-names">Jdl</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Lapatinib vs Trastuzumab in Combination with Standard EC-D Chemotherapy in the Neaodjuvant Treatment of HER2+ Patients. Results
                                    from the GEICAM 2006–14 Phase II Randomized Trial</span>. <abbr class="cit-jnl-abbrev">Cancer Research</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">71</span>(<span class="cit-issue">24</span>).</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%20vs%20Trastuzumab%20in%20Combination%20with%20Standard%20EC-D%20Chemotherapy%20in%20the%20Neaodjuvant%20Treatment%20of%20HER2%2B%20Patients.%20Results%20from%20the%20GEICAM%202006%E2%80%9314%20Phase%20II%20Randomized%20Trial&amp;author=E%20Alba&amp;author=J%20Albanell&amp;author=Jdl%20Haba&amp;publication_year=2011&amp;journal=Cancer%20Research&amp;volume=71&amp;issue=24">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">32.</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32. in text"
                           id="ref-32">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.32"
                             data-doi="10.1016/S1470-2045(11)70397-7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Untch</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Loibl</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bischoff</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44):
                                    a randomised phase 3 trial</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">135</span>–<span class="cit-lpage">144</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70397-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22257523&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300197400038&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%20versus%20trastuzumab%20in%20combination%20with%20neoadjuvant%20anthracycline-taxane-based%20chemotherapy%20%28GeparQuinto%2C%20GBG%2044%29%3A%20a%20randomised%20phase%203%20trial&amp;author=M%20Untch&amp;author=S%20Loibl&amp;author=J%20Bischoff&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=2&amp;pages=135-144">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">33.</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33. in text"
                           id="ref-33">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.33"
                             data-doi="10.1038/onc.2008.432">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scaltriti</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Verma</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Guzman</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent
                                    cell cytotoxicity</span>. <abbr class="cit-jnl-abbrev">Oncogene</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">28</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">803</span>–<span class="cit-lpage">814</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/onc.2008.432&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19060928&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000263320000003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%2C%20a%20HER2%20tyrosine%20kinase%20inhibitor%2C%20induces%20stabilization%20and%20accumulation%20of%20HER2%20and%20potentiates%20trastuzumab-dependent%20cell%20cytotoxicity&amp;author=M%20Scaltriti&amp;author=C%20Verma&amp;author=M%20Guzman&amp;publication_year=2009&amp;journal=Oncogene&amp;volume=28&amp;issue=6&amp;pages=803-814">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">34.</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34. in text"
                           id="ref-34">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.34"
                             data-doi="10.1158/0008-5472.CAN-08-4597">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scheuer</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Friess</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Burtscher</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft
                                    tumor models</span>. <abbr class="cit-jnl-abbrev">Cancer Res</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">69</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">9330</span>–<span class="cit-lpage">9336</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=69/24/9330"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">35.</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference 35. in text"
                           id="ref-35">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.35"
                             data-doi="10.1200/JCO.2011.39.2779">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Esserman</span>  <span class="cit-name-given-names">LJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berry</span>  <span class="cit-name-given-names">DA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">DeMichele</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1
                                    TRIAL--CALGB 150007/150012, ACRIN 6657</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">3242</span>–<span class="cit-lpage">3249</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/26/3242"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">36.</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36. in text"
                           id="ref-36">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.36"
                             data-doi="10.1016/S0140-6736(09)61964-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gianni</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Eiermann</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Semiglazov</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients
                                    with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel
                                    HER2-negative cohort</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">375</span>(<span class="cit-issue">9712</span>):<span class="cit-fpage">377</span>–<span class="cit-lpage">384</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(09)61964-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20113825&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000274305500025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Neoadjuvant%20chemotherapy%20with%20trastuzumab%20followed%20by%20adjuvant%20trastuzumab%20versus%20neoadjuvant%20chemotherapy%20alone%2C%20in%20patients%20with%20HER2-positive%20locally%20advanced%20breast%20cancer%20%28the%20NOAH%20trial%29%3A%20a%20randomised%20controlled%20superiority%20trial%20with%20a%20parallel%20HER2-negative%20cohort&amp;author=L%20Gianni&amp;author=W%20Eiermann&amp;author=V%20Semiglazov&amp;publication_year=2010&amp;journal=Lancet&amp;volume=375&amp;issue=9712&amp;pages=377-384">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">37.</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37. in text"
                           id="ref-37">↵</a><div class="cit ref-cit ref-journal" id="cit-106.9.dju203.37"
                             data-doi="10.1200/JCO.2011.38.8595">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">von Minckwitz</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Untch</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blohmer</span>  <span class="cit-name-given-names">JU</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast
                                    cancer subtypes</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">15</span>):<span class="cit-fpage">1796</span>–<span class="cit-lpage">1804</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/15/1796"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">Solicited Editorial<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Lisa A. Carey</span><span class="cit-sep cit-sep-two-item-separator"> and</span></li>
                           <li class="last-item"><span class="cit-auth cit-auth-type-author">William Barry</span></li>  
                        </ul><span class="cit-title">Making Sense of Dual HER2-Targeting in Early Breast Cancer? </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2014<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">106 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>9<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-elocation">dju259 </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/dju259 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>September 15, 2014 </span><span class="cit-page-count"><span class="cit-sep cit-sep-before-article-page-count">(</span>2<span class="cit-sep cit-sep-after-article-page-count"> pages)</span> </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;106/9/dju259 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/106/9/dju259.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/106/9/dju259.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/106/9/dju259.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/106/9/dju246.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/106/9/dju259.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/106/9.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2014) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    106
                                    </span><span class="slug-issue">
                                    (9):
                                    </span><span class="slug-elocation">
                                    
                                    dju203
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/dju203" class="slug-doi">10.1093/jnci/dju203</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/106/9/dju203.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/106/9/dju203.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/106/9/dju203/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=Review&amp;sortspec=date&amp;submit=Submit">Review</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;106/9/dju203" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B106%2F9%2Fdju203&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/106/9/dju203.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=106/9/dju203&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/106/9/dju203.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdju203&amp;citation=Nagayama%20et%20al.%20106%20%289%29&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B106%2F9%2Fdju203&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=25224562&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B106%2F9%2Fdju203">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B106%2F9%2Fdju203">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis%3A%20&amp;publicationDate=09%2F01%2F2014&amp;author=Aiko%20Nagayama%2C%20Tetsu%20Hayashida%2C%20Hiromitsu%20Jinno%2C%20Maiko%20Takahashi%2C%20Tomoko%20Seki%2C%20Akiko%20Matsumoto%2C%20Takeshi%20Murata%2C%20Hutan%20Ashrafian%2C%20Thanos%20Athanasiou%2C%20Koji%20Okabayashi%2C%20Yuko%20Kitagawa&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdju203&amp;volumeNum=106&amp;issueNum=9&amp;startPage=&amp;endPage=&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/106/9/dju203.full?cited-by=yes&amp;legid=jnci;106/9/dju203#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/106/9/dju203" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/106/9/dju203?access_num=/jnci/106/9/dju203"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F106%2F9%2Fdju203&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/106/9/dju203.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ANagayama%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Nagayama, A.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AKitagawa%20author%3AY.%22"
                              class="cb-art-gs-auth author-link">Articles by  Kitagawa, Y.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/106/9/dju203.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=25224562&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Nagayama%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Nagayama, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Hayashida%20T&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Hayashida, T.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Jinno%20H&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Jinno, H.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Takahashi%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Takahashi, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Seki%20T&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Seki, T.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Matsumoto%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Matsumoto, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Murata%20T&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Murata, T.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ashrafian%20H&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ashrafian, H.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Athanasiou%20T&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Athanasiou, T.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Okabayashi%20K&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Okabayashi, K.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Kitagawa%20Y&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Kitagawa, Y.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/106/9/dju203.full?related-urls=yes&amp;legid=jnci;106/9/dju203#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B106%2F9%2Fdju203&amp;current-view-path=/content/106/9/dju203.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/106/9/dju203&amp;title=Comparative%20Effectiveness%20of%20Neoadjuvant%20Therapy%20for%20HER2%E2%80%93Positive%20Breast%20Cancer%3A%20A%20Network%20Meta-Analysis+--+Nagayama%20et%20al.%20106%20%289%29+--+jnci&amp;doi=10.1093/jnci/dju203&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-5">Methods</a></li>
                        <li><a href="#sec-11">Results</a></li>
                        <li><a href="#sec-13">Results of Direct Comparisons</a></li>
                        <li><a href="#sec-16">Discussion</a></li>
                        <li><a href="#sec-17">Funding</a></li>
                        <li><a href="#notes-1">Notes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/106/9/dju203.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/106/9/dju203.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>